Risankizumab: An anti-IL-23 antibody for the treatment of psoriasis

Isabel M. Haugh, Allie K. Preston, Dario N. Kivelevitch, Alan M. Menter

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations


Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has been primarily developed for use in moderate-to-severe psoriasis. USA-based pharmaceutical company Abbvie submitted it for a Biologics License Application to the US Food and Drug Administration (FDA) in April 2018. Risankizumab is the result of a collaboration between the German company Boehringer Ingelheim and Abbvie, which together are leading the future development and commercialization of risankizumab globally. The results from Phase I to Phase III clinical trials of risankizumab show it is highly effective and its FDA-approval in 2018 is likely. In this article we provide an independent expert opinion on the efficacy and safety of risankizumab in psoriasis based on a full review of the literature.

Original languageEnglish (US)
Pages (from-to)3879-3883
Number of pages5
JournalDrug Design, Development and Therapy
StatePublished - 2018
Externally publishedYes


  • Efficacy
  • Human monoclonal antibody
  • Interleukin-23
  • Psoriasis
  • Risankizumab
  • Safety

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery


Dive into the research topics of 'Risankizumab: An anti-IL-23 antibody for the treatment of psoriasis'. Together they form a unique fingerprint.

Cite this